Carisma Therapeutics, Inc. (CARM)

Market Cap	36.01M
Revenue (ttm)	20.27M
Net Income (ttm)	-63.80M
Shares Out	41.75M
EPS (ttm)	-1.55
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	75,662
Open	0.870
Previous Close	0.867
Day's Range	0.850 - 0.870
52-Week Range	0.800 - 3.160
Beta	n/a
Analysts	Strong Buy
Price Target	12.67 (+1,369.16%)
Earnings Date	Nov 7, 2024

About CARM

Carisma Therapeutics, Inc., a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company’s ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, inc...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Employees: 107
• Stock Exchange: NASDAQ
• Ticker Symbol: CARM
• Website: https://www.carismatx.com

Financial Performance

In 2023, Carisma Therapeutics's revenue was $14.92 million, an increase of 51.71% compared to the previous year's $9.83 million. Losses were -$86.88 million, 41.9% more than in 2022.

Analyst Forecast

According to 3 analysts, the average rating for CARM stock is "Strong Buy." The 12-month stock price forecast is $12.67, which is an increase of 1,369.16% from the latest price.

Price Target

$12.67

(1,369.16% upside)

Analyst Consensus: Strong Buy